Background
Methods
Study population
Data collection
Data analysis
Results
Risk factors associated with CMV viraemia
Total n | Number with CMV (%) | CMV rate per 100,000 patient days (95% CI) |
p-value | |
---|---|---|---|---|
Total | 435 | 70 (16.1) | 18.2 (14.7, 22.5) | |
Sex | ||||
Female | 164 | 27 (16.5) | 19.1 (13.6, 26.7) | 0.893 |
Male | 272 | 43 (15.9) | 17.6 (13.4, 23.3) | |
Age 65 and over | ||||
< 65 | 396 | 58 (14.7) | 16.4 (13.0, 20.7) | 0.019 |
≥ 65 | 39 | 12 (30.8) | 46.1 (26.8, 79.4) | |
Transplant Hospital | ||||
SCGH | 232 | 33 (14.2) | 14.60 (10.58, 20.16) | 0.296 |
RPH | 206 | 40 (19.4) | 22.53 (16.93, 29.99) | |
Index graft history | ||||
First graft | 384 | 64 (16.7) | 18.8 (15.0, 23.5) | 0.425 |
Had previous graft(s) | 51 | 6 (11.8) | 14.1 (7.0, 28.2) | |
Number of grafts during follow up | ||||
Single graft | 432 | 69 (16.0) | 18.0 (14.5, 22.3) | 0.410 |
Two grafts | 3 | 1 (33.3) | 191.2 (26.9, 1357.4) | |
Donor & recipient CMV status (n = 430) | ||||
D−R−
| 49 | 0 (0) | 0 | <0.001 |
D−R+
| 115 | 13 (11.3) | 11.0 (6.5, 18.6) | |
D+R−
| 68 | 25 (36.8) | 56.8 (40.0, 80.8) | |
D+R+
| 195 | 32 (16.4) | 18.9 (13.8, 25.9) | |
HLA mismatch (index graft) (n = 432) | ||||
< 2 mismatches | 58 | 5 (8.6) | 8.3 (3.7, 18.5) | 0.153 |
≥ 2 mismatches | 371 | 65 (17.5) | 20.2 (16.2, 25.2) | |
Antibody treatment | ||||
None or before or at transplant only | 394 | 59 (30.3) | 15.0 (8.5, 26.5) | |
Post-transplant | 33 | 11 (33.3) | 18.8 (15.0, 23.7) | 0.687 |
Rejection (any) | ||||
No | 342 | 51 (14.9) | 16.3 (12.6, 21.1) | 0.205 |
Yes | 93 | 19 (20.4) | 35.3 (16.6, 35.3) | |
Rejection (severe) | ||||
No | 407 | 63 (15.5) | 16.7 (13.3, 21.1) | 0.002 |
Yes | 28 | 7 (25.0) | 38.3 (21.7, 67.4) | |
Aboriginal | ||||
No | 386 | 63 (16.3) | 18.3 (14.6, 22.9) | 0.838 |
Yes | 49 | 7 (14.3) | 17.6 (9.2, 33.8) | |
Donor aged >60 | ||||
No | 317 | 40 (12.6) | 12.9 (9.6, 17.2) | 0.002 |
Yes | 118 | 30 (25.2) | 36.4 (26.5, 50.0) | |
Deceased donor | ||||
No | 192 | 25 (13.0) | 11.4 (7.8, 16.8) | 0.017 |
Yes | 244 | 45 (18.5) | 24.8 (19.2, 32.1) |
Multivariable analysis
Variable | Adjusted Hazard Ratio (95% CI) |
p-value |
---|---|---|
Recipient aged ≥65 at transplant | 1.85 (0.96, 3.58) | 0.067 |
Donor aged ≥60 | 2.24 (1.36, 3.67) | 0.001 |
Deceased donor | 2.03 (1.18, 3.50) | 0.011 |
Donor/Recipient CMV status | ||
D−/R+ (reference) | − | − |
D+/R−
| 5.44 (2.49, 11.89) | <0.001 |
D+/R+
| 1.73 (0.84, 3.56) | 0.138 |
mTOR inhibitor | 0.31 (0.09, 1.02) | 0.054 |
Association between CMV viraemia and all-cause mortality
Variable | Number | Number of deaths (%) | Death rate per 100,000 patient days (95% CI) |
p-value |
---|---|---|---|---|
All cases | 438 | 55 (12.6) | 7.9 (6.0, 10.2) | |
Transplant Hospital | ||||
SCGH | 232 | 29 (12.5) | 7.9 (5.5, 11.3) | 1.0 |
RPH | 206 | 26 (12.6) | 7.8 (5.3, 11.5) | |
CMV viral load of ≥600 copies/ml | ||||
No | 364 | 35 (9.6) | 5.8 (4.2, 8.0) | <0.001 |
Yes | 74 | 20 (27.0) | 21.0 (13.6, 32.6) | |
CMV viral load (copies/ml) | ||||
< 600 | 364 | 35 (9.6) | 5.8 (4.2, 8.0) | |
600–4999 | 42 | 10 (23.8) | 18.7 (9.7, 35.9) | <0.001 |
≥ 5000 | 32 | 10 (31.3) | 23.5 (13.0, 42.4) | 0.001 |
Sex | ||||
Female | 166 | 25 (15.1) | 9.2 (6.2, 13.7) | 0.30 |
Male | 272 | 30 (11.0) | 7.0 (4.9, 10.0) | |
Deceased donor | ||||
No | 192 | 17 (8.9) | 5.2 (3.2, 8.3) | 0.02 |
Yes | 246 | 38 (15.5) | 10.2 (7.4, 14.0) | |
Donor aged ≥60 | ||||
No | 317 | 35 (11.0) | 6.8 (4.9, 9.5) | 0.10 |
Yes | 121 | 20 (16.5) | 10.8 (7.0, 16.8) | |
Graft failure | ||||
No | 390 | 47 (12.1) | 7.6 (5.7, 10.1) | 0.51 |
Yes | 48 | 8 (16.7) | 9.7 (4.9, 19.4) | |
Age ≥ 65 at transplant | ||||
No | 399 | 42 (10.5) | 6.5 (4.8, 8.8) | <0.001 |
Yes | 39 | 13 (33.3) | 24.2 (14.1, 41.7) | |
Lung Disease | ||||
No | 378 | 41 (10.9) | 6.8 (5.0, 9.2) | 0.02 |
Yes | 60 | 14 (23.3) | 14.6 (8.6, 24.6) | |
Cerebrovascular disease | ||||
No | 407 | 41 (10.1) | 6.2 (4.6, 8.4) | <0.001 |
Yes | 31 | 14 (45.1) | 34.5 (20.4, 58.3) | <0.001 |
Vascular disease other than cerebrovascular | ||||
No | 104 | 36 (10.8) | 6.7 (4.8, 9.3) | 0.05 |
Yes | 334 | 19 (18.3) | 11.7 (7.5, 18.4) | |
Diabetes | ||||
No | 293 | 35 (12.0) | 7.5 (5.4, 10.4) | 0.61 |
Yes | 145 | 20 (13.8) | 8.6 (5.6, 13.3) | |
HLA mismatch ≥2 | ||||
No | 373 | 6 (10.2) | 5.9 (2.6, 13.1) | 0.45 |
Yes | 59 | 49 (13.1) | 8.3 (6.2, 10.9) | |
Maximum Panel Reactive Antibody level ≥ 50% | ||||
No | 366 | 46 (12.6) | 7.8 (5.8, 10.4) | 0.62 |
Yes | 61 | 9 (14.8) | 9.2 (4.8, 17.7) | |
Any cancer diagnosis | ||||
No | 352 | 42 (11.9) | 7.5 (5.5, 10.2) | 0.51 |
Yes | 86 | 13 (15.1) | 9.2 (5.3, 15.8) | |
Aboriginal | ||||
No | 387 | 40 (10.3) | 6.4 (4.7, 8.8) | 0.001 |
Yes | 51 | 15 (29.4) | 19.3 (11.6, 32.0) | |
Any rejection | ||||
No | 302 | 37 (12.3) | 7.9 (5.7, 10.9) | 0.99 |
Yes | 136 | 18 (13.2) | 7.8 (4.9, 12.4) | |
Severe rejection | ||||
No | 404 | 49 (12.1) | 7.7 (5.8, 10.1) | 0.54 |
Yes | 34 | 6 (17.7) | 9.9 (4.4, 21.9) | |
Healthy weight (BMI 19–25) at transplant | ||||
No | 272 | 35 (12.9) | 8.3 (5.9, 11.5) | 0.78 |
Yes | 159 | 20 (12.6) | 7.6 (4.9, 11.8) | |
Current smoker | ||||
No | 398 | 48 (12.1) | 7.6 (5.7, 10.1) | 0.45 |
Yes | 40 | 7 (17.5) | 10.2 (4.9, 21.5) |
Sensitivity analysis for CMV viraemia and mortality
Variable | Adjusted Hazard Ratio (95% CI) |
p-value |
---|---|---|
CMV viral load <68 copies/ml (reference) | - | - |
CMV viral load 68–655 copies/ml | 0.63 (0.15, 2.62) | 0.52 |
CMV viral load 656–4589 copies/ml | 2.35 (1.12, 4.91) | <0.001 |
CMV viral load ≥4590 copies/ml | 3.19 (1.61, 6.31) | 0.001 |
Multivariable analysis for factors associated with all cause mortality
Variable | Adjusted Hazard Ratio (95% CI) |
p-value |
---|---|---|
CMV viral load | ||
Less than 656 copies/ml (reference) | - | |
656–4590 copies/ml | 3.25 (1.42, 7.44) | 0.007 |
≥ 4590 copies/ml | 3.94 (1.75, 8.89) | 0.012 |
Aboriginal | 3.39 (1.74, 6.63) | <0.001 |
Age ≥ 65 at transplant | 2.39 (1.10, 5.18) | 0.027 |
Cerebrovascular disease | 4.21 (1.81, 9.78) | 0.001 |
Other vascular disease | 2.21 (1.19, 4.09) | 0.012 |